Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

What Faron Pharmaceuticals Oy (LSE:FARN) Reported Concerning Bexmarilimab Combination Dosing Tolerability in the FTSE AIM All-Share

The primary clinical focus for Faron centres on its ongoing Phase 1/2 BEXMAB trial, which investigates bexmarilimab in combination with the standard-of-care hypomethylating agent azacitidine in patients with higher-risk myelodysplastic syndrome (MDS) who have failed or relapsed following prior therapies. Clinical updates presented at …

Ankur Sharma | 16 November 2026

Why 4basebio PLC (LSE:4BB) Accelerates Endotoxin-Free Synthetic DNA Purification for Gene Therapy Vectors in the FTSE AIM All-Share

TheCompetitive Advantageof 4basebio's technology lies in eliminating the reliance on traditional bacterial plasmid DNA fermentation. Conventional plasmid production is slow, technically complex, and risks contaminating clinical-grade batches with bacterial endotoxins and unmethylated DNA sequences. In contrast, 4basebio's proprietary enzymatic amplification processes synthesize pure DNA …

Ankur Sharma | 16 November 2026

How Abingdon Health plc (LSE:ABDX) Expands Regulatory Technical File Support for Lateral Flow Contract Clients in the FTSE AIM All-Share

The engine of Abingdon Health's commercial turnaround is its rapidly expanding CDMO customer base. Operating state-of-the-art automated manufacturing facilities in York and Doncaster, the company develops and manufactures lateral flow test strips for global corporate clients across infectious diseases, oncology, fertility, animal health, and …

Ankur Sharma | 16 November 2026

Why Allergy Therapeutics plc (LSE:AGY) Prioritises Cold-Chain Stability Monitoring for Depot Allergen Vaccines in the FTSE AIM All-Share

The company's clinical scientific efforts are led by Grass MATA MPL, a pivotal Phase 3Vaccinecandidate designed to treat seasonal allergic rhinitis caused by grass pollen. Concurrently, Allergy Therapeutics (LSE:AGY) is progressing preclinical and early-stage clinical evaluation of its virus-like particle (VLP) peanut allergy candidate, …

Ankur Sharma | 16 November 2026

Why Advanced Medical Solutions Group plc (LSE:AMS) Prioritises Internal Mesh Fixation Strength in Hernia Repair in the FTSE AIM All-Share

The primary operational growth catalyst for AMS is its LiquiBand family of topical cyanoacrylate tissue adhesives. In the United States hospital market, the group sells directly through specialized distributor networks, winningMarket Sharefrom legacy skin closure staples and traditional sutures. The launch of next-generation LiquiBand …

Ankur Sharma | 16 November 2026

Why AOTI Inc. (LSE:AOTI) Emphasises Hospital-to-Home Continuity of Care for Chronic Wound Oxygen Therapy in the FTSE AIM All-Share

The primary growth catalyst for AOTI is expanding commercial insurance and government reimbursement coverage across the United States healthcare ecosystem. The US Veterans Health Administration (VA) andMedicarehave established dedicated reimbursement coding for TWO2 therapy, recognizing extensive clinical trial data demonstrating superior wound closure rates …

Ankur Sharma | 16 November 2026

What Applied Nutrition PLC (LSE:APN) Reported Regarding Automated Powder Blending Homogeneity in UK Facilities

A coreCompetitive Advantagefor Applied Nutrition is its state-of-the-art, vertically integrated manufacturing and distribution headquarters in Liverpool, United Kingdom. Unlike asset-light supplementBrandaggregators that outsource production to third-party contract packers, Applied Nutrition formulates, blends, flavour-tests, and packages its products in-house under strict BRCGS food safety certifications. …

Ankur Sharma | 16 November 2026

Why Aptamer Group Plc (LSE:APTA) Prioritises Rapid Target Screening Cycles for Custom Optimer Binders in the FTSE AIM All-Share

Management has transitioned its operational focus toward securing upfront fee-for-service development contracts and long-term royalty-bearing commercial licensing agreements. By collaborating with multinational pharmaceutical corporations, agricultural bioscience enterprises, and contract development organisations, Aptamer generates serviceRevenueduring early discovery phases while retainingDownstreamRoyaltyupside upon commercial product launch. Recent …

Ankur Sharma | 16 November 2026

How Arecor Therapeutics plc (LSE:AREC) Applies Excipient Matrix Screening to Stabilise Concentrated Monoclonal Antibodies in the FTSE AIM All-Share

Following an extensive strategic review conducted by the board of directors, Arecor (LSE:AREC) executed a comprehensive capital restructuring and overhead reduction programme in late 2026. The company successfully completed a formal share fundraise to extend its operational cash runway into 2027 while reallocating scientific …

Ankur Sharma | 16 November 2026

Why AstraZeneca PLC (LSE:AZN) Prioritises Radioconjugate Isotope Supply Chain Resilience in Oncology as a FTSE 100 Constituent

The primary growth engine for AstraZeneca (LSE:AZN) is its dominant Oncology franchise, spearheaded by blockbuster targeted cancer therapies Tagrisso, Lynparza, Calquence, and Imfinzi. Concurrently, the company is pioneering the next frontier of precision cancer treatment through its industry-leading Antibody-Drug Conjugate (ADC)Partnershipwith Daiichi Sankyo, headlined …

Ankur Sharma | 16 November 2026
Support

Hi! How can we help you today?

Loading…